Updated CNS cancer guidelines and CNSide data highlighted
Plus Therapeutics posted a press release highlighting updated NCCN CNS cancer guidelines that reaffirm routine CSF testing for leptomeningeal metastases monitoring.
The release points to CNSide data showing more than double the tumor-detection sensitivity versus conventional CSF cytology in matched samples.
Plus cited contracted coverage of about 126 million lives, targeting 150 million lives and 1,250 CNSide tests in 2026.
PSTV•
